Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)

Price$5.95

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-12.51%

Price vs S&P 500 (4W)-19.20%

VGM Score41.38

Market Capitalization$589.90M

All Metrics

Book Value / Share (Quarterly)$2.23

P/TBV (Annual)11.17x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.54

Price vs S&P 500 (YTD)-26.64%

EPS (TTM)$-0.96

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-0.96

EPS (Annual)$-0.97

ROI (Annual)-47.02%

Cash / Share (Quarterly)$2.25

ROA (Last FY)-44.78%

EBITD / Share (TTM)$-1.04

ROE (5Y Avg)-338.07%

Cash Flow / Share (Annual)$-0.56

P/B Ratio3.07x

P/B Ratio (Quarterly)3.16x

Net Income / Employee (Annual)$-787,300

Net Interest Coverage (TTM)-256.31x

ROA (TTM)-51.19%

EPS Incl Extra (Annual)$-0.97

Current Ratio (Annual)15.12x

Quick Ratio (Quarterly)18.95x

3-Month Avg Trading Volume0.07M

52-Week Price Return51.73%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.63

52-Week High$12.86

EPS Excl Extra (Annual)$-0.97

CapEx CAGR (5Y)59.81%

Tangible BV CAGR (5Y)16.55%

26-Week Price Return-4.58%

Quick Ratio (Annual)14.43x

13-Week Price Return-22.87%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)19.30x

Enterprise Value$364.85M

Book Value / Share Growth (5Y)5.08%

Revenue / Employee (Annual)$0

Cash / Share (Annual)$1.55

3-Month Return Std Dev58.14%

Net Income / Employee (TTM)$-907,500

ROE (Last FY)-47.02%

Net Interest Coverage (Annual)-23.86x

EPS Basic Excl Extra (Annual)$-0.97

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.96

ROI (TTM)-53.51%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.60

Price vs S&P 500 (52W)27.36%

Year-to-Date Return-19.28%

5-Day Price Return-12.96%

EPS Normalized (Annual)$-0.97

ROA (5Y Avg)-84.11%

Month-to-Date Return-16.11%

Cash Flow / Share (TTM)$-1.44

EBITD / Share (Annual)$-0.96

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-104.64%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.96

P/TBV (Quarterly)8.43x

P/B Ratio (Annual)4.61x

Book Value / Share (Annual)$1.58

Price vs S&P 500 (13W)-31.13%

Beta1.02x

Revenue / Share (TTM)$0.00

ROE (TTM)-53.51%

52-Week Low$5.20

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

4.11

4.27

About

Eupraxia Pharmaceuticals is a clinical-stage biotech company developing extended-release, locally delivered therapeutics using its proprietary Diffusphere technology. Its lead candidate, EP-104, targets osteoarthritis and eosinophilic esophagitis, addressing unmet medical needs through improved drug delivery profiles.